GlaxoSmithKline to finalize $15 billion bid for Pfizer OTC unit

UK drugmaker GlaxoSmithKline is finalizing a $15 billion bid for Pfizer’s over-the-counter drugs business, according to reports in the Financial Times (FT), The Times (of London) and others. The Financial Times reported that Glaxo would bid at least $14 billion for the unit and would not go higher than $16 billion. The Times report indicated Glaxo would spend up to $15 billion. If Glaxo’s bid is successful, it would make the company the world’s largest manufacturer of non-prescription drugs. Other companies interested in the division include Colgate Palmolive, Bayer and Johnson & Johnson. Pfizer said early this year that it would consider selling or spinning off its consumer-products unit, which markets brands including Listerine, Sudafed and Lubriderm. The division’s sales rose 10 % to $3.8 billion last year as sales of Pfizer’s prescription products fell 4% to $44 billion.
You must be a registered member of MMM to post a comment.

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.